| 1994 |
Established Yantai Luye Pharmaceutical Co., Ltd. to engage in the manufacture and sale of pharmaceutical drugs and active ingredients. |
| |
| 1995 |
Commenced production of the natural active ingredient, Sodium Aescinate and our main natural drug, Maitongna (Sodium Aescinate for Injection) |
| |
| 1997 |
Incorporated Yantai Luye Drugs Trading Co., Ltd. to distribute the products of other pharmaceutical manufacturers in the PRC. |
| |
| 1998 |
Established our R&D centre to focus on R&D to develop new natural active ingredients and drugs with new formulations. |
| |
| 1999 |
Successfully launched Nuosen® (Sodium Pantoprazole for Injection) a newly formulated prescription drug used for the treatment of gastroenterological ailments, throughout the PRC.
Granted a "Post-doctorate Scientific Research Work-Station" by the State Personnel Ministry.
|
| |
| 2000 |
Obtained GMP certification for our production line and manufacturing process for tablets, capsules and granules. Our R&D centre was recognised by the Shandong Natural Drug Engineering Research and Development Centre".
Obtained GMP certification for our lyophilized powder injection production line and manufacturing process.
|
| |
| 2001 |
Nominated by the Ministry of Science and Technology as a production base to industrialise results of the National High Tech Research and Development program ("State 863 Programme"). |
| |
| 2002 |
Launched Olai® (Compound Sodium Aescinate Gel)manufactured from the natural ingredient, Sodium Aescinate.
Obtained patent for the composition with low toxicity for anti-inflammation and anti-exudation of Sodium Aescinate from the US Patent and Trademark Office for 20 years.
|
| |
| 2003 |
Obtained GMP certification for our production line and manufacturing process for gel and raw material, Sodium Aescinate.
Launched Lutingnuo® (Reduced Glutathione for Injection) principally used for the treatment of liver ailments.
|
| |
| 2004 |
Listed on the Main Board of the SGX – ST on 5 May 2004. |
| |
|
| |
Significant Developments Since IPO – Year 2004
| 17 May |
Technical co-operation with Kyowa Hakko Kogyo |
| 14 July |
Argine Aescinate for Injection has obtained clinical trials approval from SFDA |
| 4 Aug |
Set up Pharmaceutical College with Yantai University |
| 16 Aug |
Elcatonin for Injection has obtained manufacturing approval from SFDA |
| 21 Sep |
Nuosen® (Sodium Pantoprazole for Injection) listed as one of the approved drugs under the "National Health Insurance List" |
| |
Meglumine Adenosine Cyclophosphate for Injection obtained manufacturing licence and a New Drug Certification from the SFDA of the PRC |
| 9 Dec |
Lutingnuo® (Reduced Gluthathione for Injection) listed as a "National Leading New Product" by four state departments, namely the Ministry of Science and Technology, the Ministry of Trade, The State Quality Technology Supervisory Bureau and the State Environmental Protection Bureau |
| |
Elcatonin for Injection listed as one of the approved drugs under the "National Health Insurance List" |
|
| |
| 2005 |
| 11 Jan |
Strategic alliance with Biomedica Foscama of Italy for joint development of drugs for sale in Asia and Europe. |
| 07 Feb |
Obtained patent rights for its bi-weekly or monthly sustained-release microspheres for the injection of Huperzine A drug in the PRC. |
| 21 Feb |
Obtained State Food and Dug Adminstration approval for clinical trials for Pantoprazole Sodium delayed-release pellets capsule. |
| 08 Mar |
Obtained patent rights for Arginine Aescinate for injection, an improved version of our key product, Maitongna. |
| 04 Apr |
Exclusive supply agreement with Dr. Reddy's Laboratories Limited of India to import FDA/EMEA-approved Pantoprazole Sodium API into the PRC. |
| 26 May |
Alliance agreement with Napo Pharmaceuticals Inc. of United States for exclusive rights to develop, market and distribute Crofelemer derived products in PRC. |
| 27 Jun |
Collaborative agreement with Sochinaz SA of Switzerland for the exclusive supply of key ingredient MT103-I for a new drug under development. |
| 02 Aug |
Technical collaboration with Temasek Life Sciences Laboratories of Singapore for use of its proprietary zebrafish screening technology to identify high-value drugs more efficiently. |
| 29 Sep |
Obtained State Food and Dug Adminstration approval for clinical trials of proprietary drugs Huperzine A Fast Disintegrating Tablets and Huperzine A Sustained-release Tablets. |
| 13 Oct |
Entered Vietnamese market through appointed distributors. |
| 14 Nov |
Memorandum of Understanding with Global Harvest Pharmaceutical Ltd. ("GHP") of United States, to assist and appoint Asiapharm as qualified pharmaceutical manufacturer under international regulatory standards. |
| 28 Nov |
Obtained State Food and Dug Adminstration approval for clinical trials of Lutingnuo® capsules. |
| 13 Dec |
Announced the expected launch of Ximingting® in FY2006, a natural proprietary drug used as an alternative to Hormone Replacement Therapy in the treatment of menopausal symptoms. |
|
| |
| 2006 |
| May |
|
| |
AsiaPharm places 80 million new ordinary shares to strategic investors, boosting corporate profile and raising funds of RMB 322.0 million for future expansion |
| |
AsiaPharm launches New Formulation Otong ( 欧通) - an external use pain relief natural drug, which has significant potential for integration and marketing within OTC drug portfolio |
| |
AsiaPharm acquires minority interests of trading subsidiary - Luye Drug Trading - in strategic alignment exercise to focus on higher - margin business |
| June |
|
| |
AsiaPharm receives new drug approval for Sailimai (赛立迈) - a new formulation for treating acute and chronic diarrhoea |
| October |
|
| |
AsiaPharm receives new drug approval for Pantoprazole Sodium Enteric - coated Pellet Capsule (泮托拉唑微丸胶囊), a new oral formulation for the treatment of Chronic Peptic and Gastric ulcers |
| |
AsiaPharm acquires proprietary cancer treatment injection drug CMNa ® (希美纳) - the only approved chemical sensitizer for radiotherapy in the world, further boosting its Oncology drug portfolio |
| |
|
|
| |
| 2007 |
| January |
|
| |
AsiaPharm buys Nanjing based pharmaceutical group specializing in Oncology for RMB 345.0 million, enhancing its Oncology drug portfolio and accelerating its penetration into the PRC oncology drug sector |
| |
AsiaPharm appoints exclusive Korean development agency for proprietary oncology drug CMNa ® (希美纳); underlining its global market penetration initiative |
| February |
|
|
AsiaPharm's proprietary drug Ximingting® (希明婷) endorsed by key medical institutions for its effectiveness in treating menopausal symptons in extensive clinical trials |
| |
AsiaPharm seals agreement to sell proprietary pharmaceutical products to Pakistan, further expanding its regional market presence |
| August |
|
|
Seals exclusive PRC distribution agreement with LG Life Sciences Ltd for Osteoarthritis drug; additional revenue stream expected from FY2008. |
| November |
|
|
AsiaPharm completes acquisition of 43% interest in WBL Peking University Biotech Co. Ltd & its subsidiaries ("WPU"), a Beijing-based company with leading anti-cholesterol drug – Xuezhikang (血脂康®), reaffirming AsiaPharm's position as a leading pharmaceutical group in the PRC |
| |
AsiaPharm completes acquisition of 100% interest in Wearnes Biotech & Medicals (1998) Pte Ltd& its subsidiary ("WBM"), a Singapore pharmaceutical distributor for S$2.1 million; expanding the Group's distribution network in OTC drugs to South-east Asia and other countries. |
| December |
|
| |
AsiaPharm awards exclusive PRC distribution agreement for its proprietary neurology drug
JinSiPing (金思平®) to international pharmaceutical conglomerate Sandoz, a Novartis company. |
| |
|
| |
|
|
Milestones